Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Resistance to BRAF inhibitors: A lesson from clinical observations].

Medecine sciences : M/S - 1 Jan 2000

Dahmani Cylia, Corre Eulalie, Dandou Sarah, Mangé Alain, Radulescu Ovidiu, Coopman Peter J, Cuq Pierre, Larive Romain M

Abstract excerpt

The MAPK/ERK pathway is an essential intracellular signaling pathway. Its deregulation is involved in tumor transformation and progression. The discovery of activating mutations of BRAF in various cancers has opened new therapeutic avenues with BRAF protein kinase inhibitors. Depending on the type of cancers, these inhibitors have shown either insufficient efficacy due to primary resistance of tumor cells or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 35766855
DOI: 10.1051/medsci/2022083

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Resistance to BRAF inhibitors: A lesson from clinical observations].PMID 35766855Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant CancersSemantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

[BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].Semantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

[Mechanisms of resistance to anti-BRAF treatments].Semantic proximity Read ↗

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Semantic proximity Read ↗

[Progress of anti-tumor study based on BRAF].Semantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future ProspectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.